New imaging study aims to unlock HER2 secrets in lung cancer
NCT ID NCT07436858
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times
Summary
This study uses a special PET scan to track a tracer called 89Zr-trastuzumab in people with advanced lung cancer that has HER2 changes. The goal is to see if the tracer builds up differently in tumors with HER2 mutations versus those with too much HER2 protein. About 20 adults will take part to help researchers better understand these differences.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 EXPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Netherlands Cancer Institute - Antoni van Leeuwenhoek
Amsterdam, North Holland, 1066CX, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Family support may be key to easing lung cancer surgery stress
- Can a drop of blood predict disease years before it strikes?
- Blood, urine, and stool may hold the key to predicting a serious side effect of lung cancer treatment
- Microwave ablation vs. radiotherapy: which Non-Surgical option works best for early lung cancer?
- Double-Targeted therapy aims to outsmart Hard-to-Treat lung cancer